Journal of the European Academy of Dermatology and Venereology : JEADVLetter
06
May
2025
Real-world experience of multiple switches between adalimumab biosimilars in patients with psoriasis.
No abstract available
References:
Loft N, Egeberg A, Rasmussen MK, Bryld LE, Nissen CV, Dam TN, et al. Outcomes following a mandatory nonmedical switch from adalimumab originator to adalimumab biosimilars in patients with psoriasis. JAMA Dermatol. 2021;157(6):676–683.
Cohen AD, Vender R, Naldi L, Kalb RE, Torres T, Rajagopalan M, et al. Biosimilars for the treatment of patients with psoriasis: a consensus statement from the biosimilar working Group of the International Psoriasis Council. JAAD Int. 2020;1(2):224–230.
Blauvelt A, Lacour JP, Fowler JF, Weinberg JM, Gospodinov D, Schuck E, et al. Phase III randomized study of the proposed adalimumab biosimilar GP2017 in psoriasis: impact of multiple switches. Br J Dermatol. 2018;179(3):623–631. https://doi.org/10.1111/bjd.16890
Ribaldone DG, Tribocco E, Rosso C, Armandi A, Vernero M, Bugianesi E, et al. Switching from biosimilar to biosimilar adalimumab, including multiple switching, in Crohn's disease: a prospective study. J Clin Med. 2021;10(15):3387.
Yiu ZZN, Becher G, Kirby B, Laws P, Reynolds NJ, Smith CH, et al. Drug survival associated with effectiveness and safety of treatment with guselkumab, ixekizumab, secukinumab, ustekinumab, and adalimumab in patients with psoriasis. JAMA Dermatol. 2022;158(10):1131–1141.